Emma Dave

USPTO Granted Patents = 11 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 62(Granted Patents)

Company Filing History:

Years Active: 2014-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428497 - Multispecific antibody constructs (2025-09-30),

2. 11427650 - Dual specificity antibody fusions (2022-08-30),

3. 11401349 - Single linker FabFv antibodies and methods of producing same (2022-08-02),

4. 11345760 - Multispecific antibody constructs (2022-05-31),

5. 11091542 - Antibody molecules which bind TNF alpha (2021-08-17),

6. 10457748 - Single linker FabFv antibodies and methods of producing same (2019-10-29),

7. 10421816 - Multivalent antibodies (2019-09-24),

8. 10100130 - Dual specificity antibody fusions (2018-10-16),

9. 9828438 - Dual specificity antibody fusions (2017-11-28),

10. 9309327 - Dual specificity antibody fusions (2016-04-12),

11. 8629246 - Dual specificity antibody fusions (2014-01-14),

Title: **Innovations by Inventor Emma Dave**

Introduction

Emma Dave, an accomplished inventor based in Slough, GB, has made significant contributions in the field of biotechnology with a total of 10 patents to her name. Her expertise focuses on the development of innovative antibody fusion proteins that hold potential in therapeutic applications.

Latest Patents

Among her latest patents is a groundbreaking invention related to dual specificity antibody fusions. This invention provides fusion proteins that combine an antibody fragment specific to one antigen with a single-domain antibody targeting a second antigen. This innovative approach could enhance the therapeutic efficacy of treatments by simultaneously targeting multiple antigens.

Additionally, she has developed a patent for single linker FabFv antibodies, which details a multi-specific antibody molecule composed of three distinct polypeptides. This detailed framework improves the understanding and creation of binding domains for therapeutic use, extending to pharmaceutical formulations, DNA constructs, and methods for expressing these constructs in host cells.

Career Highlights

Emma has worked with prominent companies in the biotechnology sector, including UCB Biopharma and UCB Pharma, S.A. Her work has positioned her as a valuable asset in the development of sophisticated antibody-related treatments.

Collaborations

Throughout her career, Emma has collaborated with esteemed colleagues such as David Paul Humphreys and Sam Philip Heywood. These collaborations have likely enhanced her research output and innovation capacity, creating new avenues in the field of biopharmaceuticals.

Conclusion

Emma Dave's impressive portfolio of patents and her innovative work in the biotechnology field demonstrate her skill and dedication as an inventor. Her contributions have the potential to significantly impact medical treatments and therapies, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.